For the Inventor, By the Inventor

Enter assignee name

Boulder, CO, United States of America

Inscripta, Inc.

USPTO Granted Patents = 166

% Expired Patents = 1.8

CIPO Patents = 1

EPO Patents = 3

Trademarks = 9

Forward Citations = 1,931

Loading Chart...

Loading Chart...

65 inventors (with patents filed for the assignee):

Phillip Belgrader (68 out of 124 patents)

Don Masquelier (68 out of 69 patents)

Andrew Garst (63 out of 78 patents)

4. Jorge Bernate (50 out of 50 patents)

5. Ryan T Gill (36 out of 69 patents)

6. Richard Fox (31 out of 31 patents)

7. Aamir Mir (25 out of 25 patents)

8. Benjamin Mijts (22 out of 22 patents)

9. Bruce Chabansky (22 out of 22 patents)

10. Kevin D Ness (22 out of 128 patents)

11. Juhan Kim (21 out of 21 patents)

12. Kyle Seamon (20 out of 20 patents)

13. Tian Tian (17 out of 17 patents)

14. Stephen Federowicz (17 out of 17 patents)

15. Michael Graige (16 out of 16 patents)

Core Competencies:

CRISPR Systems

Nucleic Acid Editing

Engineered Enzymes

Automated Detection

Genome Editing

RNA Aptamers

Nuclease Activity

Multiplex Editing

Cell Processing

Electroporation

Viral Delivery

Barcoded Libraries

166 patents: Sort by Forward Citations

1. 12416008 - Compositions and methods of use for small-molecule regulation of CRISPR-Cas9 activity using RNA aptamers (2025-09-16),

2. 12195775 - Engineered enzymes and bioproduction of bakuchiol (2025-01-14),

3. 12195749 - Nucleic acid-guided nucleases (2025-01-14),

4. 12180502 - Nucleic acid-guided nucleases (2024-12-31),

5. 12146170 - Engineered enzyme (2024-11-19),

6. 11965186 - Nucleic acid-guided nickases (2024-04-23),

7. 11965154 - Detection of nuclease edited sequences in automated modules and instruments (2024-04-23),

8. 11891609 - Methods for increasing observed editing in bacteria (2024-02-06),

9. 11884924 - Dual strand nucleic acid-guided nickase editing (2024-01-30),

10. 11845932 - Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells via viral delivery (2023-12-19),

11. 11787841 - Rationally-designed mutations to the thrA gene for enhanced lysine production in (2023-10-17),

12. 11746347 - Simultaneous multiplex genome editing in yeast (2023-09-05),

13. 11739290 - Instruments, modules, and methods for improved detection of edited sequences in live cells (2023-08-29),

14. 11697826 - Nucleic acid-guided nucleases (2023-07-11),

15. 11685889 - Detection of nuclease edited sequences in automated modules and instruments (2023-06-27),

Company Overview

Inscripta, Inc. is a biotechnology company based in Boulder, Colorado, specializing in nucleic acid editing technologies. The company focuses on advancing CRISPR systems and engineered enzymes to enable precise genome editing. Inscripta's innovative platforms facilitate automated detection and multiplex editing, enhancing the capabilities of researchers in genetic engineering. By developing tools for RNA aptamers and optimizing nuclease activity, Inscripta aims to transform the landscape of genetic research and therapeutic applications.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

166 Patents

#5 in Boulder, CO

#47 in Colorado

#2,398 in US

#4,968 in the World

Boulder, CO, United States of America

Inscripta, Inc.

Forward Citations = 1,931

65 inventors:

Phillip Belgrader (68 out of 124 patents)

Don Masquelier (68 out of 69 patents)

Andrew Garst (63 out of 78 patents)

4. Jorge Bernate (50 out of 50 patents)

5. Ryan T Gill (36 out of 69 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Inscripta, Inc.. Retrieved from https://idiyas.com/company/inscripta

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…